SQ109
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Michael Hoelscher, Sequella, Inc.
Conditions
Helicobacter Pylori InfectionTB Multi-drug ResistantTuberculosisTuberculosis, Pulmonary
Phase 1
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
CompletedNCT00866190
Start: 2009-04-30End: 2009-11-30Updated: 2011-11-07
Phase IC Study of Safety and PK of SQ109 300mg Daily
CompletedNCT01358162
Start: 2010-11-30End: 2011-04-30Updated: 2013-05-14
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
CompletedNCT01585636
Start: 2006-09-30End: 2007-02-28Updated: 2013-08-19
Effects of SQ109 on QTc Interval in Healthy Subjects
WithdrawnNCT01874314
End: 2015-12-31Updated: 2014-03-24
Phase 2
Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB
CompletedNCT01218217
Start: 2010-11-30End: 2012-05-31Updated: 2013-01-14
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
WithdrawnNCT01252108
Start: 2012-03-31End: 2015-08-31Updated: 2015-11-17
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
CompletedNCT01785186
Start: 2013-04-30End: 2015-03-31Updated: 2017-09-20